Fulgent Genetics (FLGT) Long-Term Investments (2016 - 2026)

Fulgent Genetics has disclosed Long-Term Investments across 11 years of filings, most recently posting $294.3 million for Q2 2026.

• In Q2 2026, Long-Term Investments fell 39.25% year-over-year to $294.3 million; the TTM figure through Jun 2026 stood at $294.3 million (down 39.25% YoY), while the FY2025 annual figure was $369.3 million, down 35.26% from the prior year.
• Long-Term Investments came in at $294.3 million for Q2 2026 at Fulgent Genetics, down from $328.3 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $602.2 million in Q3 2024 to a low of $294.3 million in Q2 2026.
• Average Long-Term Investments over 5 years is $431.5 million, with a median of $413.7 million recorded in 2022.
• Year-over-year, Long-Term Investments surged 71.47% in 2022 and sank 39.25% in 2026.
• Over 5 years, Long-Term Investments stood at $326.6 million in 2022, then gained by 29.67% to $423.6 million in 2023, then surged by 34.65% to $570.4 million in 2024, then sank by 35.26% to $369.3 million in 2025, then slipped by 20.3% to $294.3 million in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $294.3 million in Q2 2026, $328.3 million in Q1 2026, and $369.3 million in Q4 2025.